Literature DB >> 22975556

Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor.

Naoki Kubo1, Taishi Harada, Satoshi Anai, Kohei Otsubo, Yasuto Yoneshima, Kayo Ijichi, Takaomi Koga, Koichi Takayama, Yoichi Nakanishi.   

Abstract

A 26-year-old man with unresectable inflammatory myofibroblastic tumor (IMT) presented with multiple metastases in the thoracic vertebra and lymph nodes as detected by positron emission tomography (PET) received chemotherapy with carboplatin plus paclitaxel. After three cycles of chemotherapy, fluorine-18-fluorodeoxyglucose (FDG)-PET/CT revealed tumor regression and significant reduction of FDG uptake in all lesions. The patient received six cycles of chemotherapy without any severe adverse event, and there was no sign of disease progression for seven months. This regimen is well tolerated and may be considered the treatment of choice for unresectable IMT.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22975556     DOI： 10.2169/internalmedicine.51.7599

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  9 in total

1.  Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?

Authors:  Nikolaos Panagiotopoulos; Davide Patrini; Lasha Gvinianidze; Wen Ling Woo; Elaine Borg; David Lawrence
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

2.  Computed tomography appearance of inflammatory myofibroblastic tumor in the abdomen: CT features and pathologic correlation.

Authors:  Bo Liu; Junlong Xu; Jiaxin Wang; Hongguang Fan; Xuan Ang; Wenming Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  A case of recurrent pulmonary inflammatory myofibroblastic tumor with aggressive metastasis after complete resection.

Authors:  Chae Ho Moon; Jong Ho Yoon; Geon Wook Kang; Seong Hyeon Lee; Jeong Su Baek; Seo Yun Kim; Hye-Ryoun Kim; Cheol Hyeon Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-10-29

4.  Relapsed and unresectable inflammatory myofibroblastic tumor responded to chemotherapy: A case report and review of the literature.

Authors:  Yasuhiro Maruyama; Toshirou Fukushima; Daisuke Gomi; Takashi Kobayashi; Nodoka Sekiguchi; Akiyuki Sakamoto; Shigeru Sasaki; Keiko Mamiya; Tomonobu Koizumi
Journal:  Mol Clin Oncol       Date:  2017-08-18

5.  Genetic Testing and Immunotherapy for Intracranial Inflammatory Myofibroblastic Tumor: A Case Report.

Authors:  Xiangji Meng; Lei Zhang; Qi Wang; Jimin Chen; Chunmei Zhang; Rongjie Tao; Yong Wang
Journal:  Onco Targets Ther       Date:  2022-04-01       Impact factor: 4.147

6.  Common Presentation of Uncommon Disease: Inflammatory myofibroblastic tumor of the lung, case report.

Authors:  Safwat Eldaabossi; Lotfi Maghmoul; Elsaid Lotfy; Ahmad Antar; Yasser Elghoneimy; Hameed Aljawad; Ayman Ghoneim
Journal:  Respir Med Case Rep       Date:  2022-04-26

7.  Inoperable inflammatory myofibroblastic tumour of the para-nasal sinuses and orbit with recurrence responding to methotrexate and prednisolone: a case report.

Authors:  Mitrakrishnan Rayno Navinan; Isurujith Liyanage; Sandamalee Herath; Jevon Yudhishdran; Chrishan Shivanthan; Dulani Beneragama; Aruna Kulatunga
Journal:  BMC Res Notes       Date:  2015-02-04

8.  Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).

Authors:  Xavier Garcia del Muro; Enrique de Alava; Vicenç Artigas; Silvia Bague; Alejandro Braña; Ricardo Cubedo; Josefina Cruz; Nuria Mulet-Margalef; Jose A Narvaez; Oscar Martinez Tirado; Claudia Valverde; Ramona Verges; Joan Viñals; Javier Martin-Broto
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-12       Impact factor: 3.333

9.  Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.

Authors:  Danila Comandini; Fabio Catalano; Massimiliano Grassi; Guido Pesola; Rossella Bertulli; Antonio Guadagno; Bruno Spina; Matteo Mascherini; Franco De Cian; Federico Pistoia; Sara Elena Rebuzzi
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.